Cargando…

Genetic Association of Drug Response to Erlotinib in Chinese Advanced Non-small Cell Lung Cancer Patients

The efficacy of erlotinib treatment for advanced non-small cell lung cancer (NSCLC) is due to its action as an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI). Patients treated with erlotinib experience different drug responses. The effect of germline mutations on therapeutic r...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Cong, Chen, Fang, Liu, Yichen, Xu, Qingqing, Guo, Liang, Zhang, Xiaoqing, Ruan, Yunfeng, Shi, Ye, Shen, Lu, Li, Mo, Du, Huihui, Sun, Xiaofang, Ma, Jingsong, He, Lin, Qin, Shengying
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2018
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5904969/ https://www.ncbi.nlm.nih.gov/pubmed/29695969 http://dx.doi.org/10.3389/fphar.2018.00360

Ejemplares similares

Functional Characterization of Human CYP2C9 Allelic Variants in COS-7 Cells
por: Du, Huihui, et al.
Publicado: (2016)

Genetic Association of Curative and Adverse Reactions to Tyrosine Kinase Inhibitors in Chinese advanced Non-Small Cell Lung Cancer patients
por: Ruan, Yunfeng, et al.
Publicado: (2016)

Discovery of Novel Biomarkers of Therapeutic Responses in Han Chinese Pemetrexed-Based Treated Advanced NSCLC Patients
por: Zhang, Xiaoqing, et al.
Publicado: (2019)

Methylome-wide association study of different responses to risperidone in schizophrenia
por: Du, Huihui, et al.
Publicado: (2022)

Genetic Association of Olanzapine Treatment Response in Han Chinese Schizophrenia Patients
por: Zhou, Wei, et al.
Publicado: (2019)

Two Novel Loci of RELN Associated With Antipsychotics Response in Chinese Han Population
por: Xu, Qingqing, et al.
Publicado: (2020)

Novel genetic susceptibility loci identified by family based whole exome sequencing in Han Chinese schizophrenia patients
por: Li, Mo, et al.
Publicado: (2020)

Design, Synthesis, and Antitumor Activity of Erlotinib Derivatives
por: Mao, Long-fei, et al.
Publicado: (2022)

Erlotinib Resistance in Lung Cancer: Current Progress and Future Perspectives
por: Tang, Joy, et al.
Publicado: (2013)

Functional characterization of the chlorzoxazone 6-hydroxylation activity of human cytochrome P450 2E1 allelic variants in Han Chinese
por: Wang, Ting, et al.
Publicado: (2020)

Design, synthesis and biological evaluation of erlotinib-based IDO1 inhibitors
por: Hou, Xi-xi, et al.
Publicado: (2022)

Synthesis and Antitumor Activity of Erlotinib Derivatives Linked With 1,2,3-Triazole
por: Deng, Peng, et al.
Publicado: (2022)

Dual Targeting EGFR and STAT3 With Erlotinib and Alantolactone Co-Loaded PLGA Nanoparticles for Pancreatic Cancer Treatment
por: Bao, Shihui, et al.
Publicado: (2021)

FGFC1 Selectively Inhibits Erlotinib-Resistant Non-Small Cell Lung Cancer via Elevation of ROS Mediated by the EGFR/PI3K/Akt/mTOR Pathway
por: Yan, Shike, et al.
Publicado: (2022)

Luteolin enhances erlotinib’s cell proliferation inhibitory and apoptotic effects in glioblastoma cell lines
por: Powe, Erika, et al.
Publicado: (2022)

Efficacy and Safety of Apatinib for the Treatment of Advanced or Recurrent Cervical Cancer: A Single-Arm Meta-Analysis Among Chinese Patients
por: Huang, Da, et al.
Publicado: (2022)

Systematic Functional Study of Cytochrome P450 2D6 Promoter Polymorphisms in the Chinese Han Population
por: Gong, Xueli, et al.
Publicado: (2013)

Population pharmacokinetic study of pemetrexed in chinese primary advanced non-small cell lung carcinoma patients
por: Cao, Peng, et al.
Publicado: (2022)

Review of erlotinib in the treatment of advanced non-small cell lung cancer
por: Ganjoo, Kristen N, et al.
Publicado: (2007)

Integrating Evidence of the Traditional Chinese Medicine Collateral Disease Theory in Prevention and Treatment of Cardiovascular Continuum
por: Cheang, Iokfai, et al.
Publicado: (2022)

Hypoglycemic effects of dendrobium officinale leaves
por: Lv, Ming, et al.
Publicado: (2023)

Population pharmacokinetic analysis of TQ-B3203 following intravenous administration of TQ-B3203 liposome injection in Chinese patients with advanced solid tumors
por: Li, Xiaoqing, et al.
Publicado: (2023)

Biodegradable Nanoparticles Mediated Co-delivery of Erlotinib (ELTN) and Fedratinib (FDTN) Toward the Treatment of ELTN-Resistant Non-small Cell Lung Cancer (NSCLC) via Suppression of the JAK2/STAT3 Signaling Pathway
por: Chen, Donglai, et al.
Publicado: (2018)

Effects of erlotinib therapy on [(11)C]erlotinib uptake in EGFR mutated, advanced NSCLC
por: Bahce, Idris, et al.
Publicado: (2016)

Erlotinib in the treatment of advanced pancreatic cancer
por: Kelley, Robin K, et al.
Publicado: (2008)

Maintenance Chemotherapy With Chinese Herb Medicine Formulas vs. With Placebo in Patients With Advanced Non-small Cell Lung Cancer After First-Line Chemotherapy: A Multicenter, Randomized, Double-Blind Trial
por: Wang, Qin, et al.
Publicado: (2018)

Polymorphisms of Drug-Metabolizing Enzymes and Transporters Contribute to the Individual Variations of Erlotinib Steady State Trough Concentration, Treatment Outcomes, and Adverse Reactions in Epidermal Growth Factor Receptor–Mutated Non-Small Cell Lung Cancer Patients
por: Liao, Dehua, et al.
Publicado: (2020)

Role of erlotinib in the targeted treatment of non-small-cell lung cancer in Chinese patients
por: Li, Wei, et al.
Publicado: (2014)

Afatinib vs erlotinib for second-line treatment of Chinese patients with advanced squamous cell carcinoma of the lung
por: Lu, Shun, et al.
Publicado: (2018)

Advances in the treatment of pancreatic cancer with traditional Chinese medicine
por: Zhang, Yanhua, et al.
Publicado: (2023)

Indole-3-Carbinol Selectively Prevents Chronic Stress-Induced Depression-but not Anxiety-Like Behaviors via Suppressing Pro-Inflammatory Cytokine Production and Oxido-Nitrosative Stress in the Brain
por: Pan, Shengying, et al.
Publicado: (2022)

The Chinese Herbal Prescription JieZe-1 Inhibits Membrane Fusion and the Toll-like Receptor Signaling Pathway in a Genital Herpes Mouse Model
por: Duan, Qianni, et al.
Publicado: (2021)

Repairing the intestinal mucosal barrier of traditional Chinese medicine for ulcerative colitis: a review
por: Zong, Yichen, et al.
Publicado: (2023)

Development of Certain Protein Kinase Inhibitors with the Components from Traditional Chinese Medicine
por: Liu, Minghua, et al.
Publicado: (2017)

Insights of Chinese herbal medicine for mitochondrial dysfunction in chronic cerebral hypoperfusion induced cognitive impairment: Existed evidences and potential directions
por: Wang, Yefei, et al.
Publicado: (2023)

Erlotinib ‘dosing-to-rash’: a phase II intrapatient dose escalation and pharmacologic study of erlotinib in previously treated advanced non-small cell lung cancer
por: Mita, A C, et al.
Publicado: (2011)

Bevacizumab plus erlotinib versus erlotinib alone for advanced EGFR-mutant non-small cell lung cancer: a meta-analysis of randomized clinical trials
por: Li, Ruijian, et al.
Publicado: (2023)

Comparing Efficacy of Erlotinib and Bevacizumab Combination with Erlotinib Monotherapy in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC): A Systematic Review and Meta-Analysis
por: Sakharkar, Prashant, et al.
Publicado: (2023)

Recent Advances in Traditional Chinese Medicine for Treatment of Podocyte Injury
por: Yao, Tianwen, et al.
Publicado: (2022)

Application of advanced technology in traditional Chinese medicine for cancer therapy
por: Ke, Gaofeng, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_td33nrlqbq471ps5ckfgf75n70